The merger between Oneness Biotech and Fountain Biopharma makes the pipeline and resources integrated. The pipeline will include a late-stage drug to be launched in global market as well as new drugs in earlier clinical stage in immunology. This merger will strengthen the R&D capability in favor of global collaboration and competition.
關閉
建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?
-
開啟新分頁(紅色框)
-
於搜尋框中打入Edge(紅色框)，並按搜尋(藍色框)
-
點擊【立即啟動】(藍框處)打開 Microsoft Edge
